Colorectal Cancer (CRC) Completed Phase 2 Trials for Gefitinib (DB00317)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

IndicationStatusPhase
DBCOND0031867 (Colorectal Cancer (CRC))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00025142
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal CancerTreatment
NCT00025350
Gefitinib in Treating Patients With Recurrent Metastatic Colorectal CancerTreatment
NCT00030524
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal CancerTreatment